MJFF's progress in markers

The Michael J. Fox Foundation for Parkinson's Research has taken two major steps toward its goal of identifying clinical populations in which new therapies for Parkinson's disease can be tested. Last week, the foundation made available the first set of data and samples from its LRRK2 Cohort Consortium and presented preliminary data from its Parkinson's Progression Marker Initiative.

Now, the LRRK2 Cohort Consortium will conduct longitudinal studies in its enrolled participants, whereas the Parkinson's Progression Marker Initiative (PPMI) aims to confirm the preliminary findings in the full study cohort. Additionally, the PPMI is planning collaborations with the Alzheimer's Association's Alzheimer's Disease Neuroimaging Initiative (ADNI)...